2019 is already shaping up to be another important year for anti-CGRP therapies. In the USA, the 4th monoclonal antibody for migraine prevention, eptinezumab, is undergoing regulatory review, while galcanezumab has received priority review for episodic cluster headache prevention. Hot on their heels, ubrogepant has become the first gepant submitted for regulatory approval for acute migraine treatment.

Recently published guidance from the European Headache Federation reviews evidence supporting anti-CGRP therapies and provides expert opinion on their use in daily practice.

Catch up at:

Alder files for US approval of eptinezumab »

Emgality (galcanezumab) receives US priority review for episodic cluster headache prevention »

Ubrogepant licence application for acute migraine treatment accepted by FDA »

European Headache Federation publishes CGRP therapy guidelines »

For all the other recent migraine news featured on the CGRP Forum click here »